Burning Rock Biotech Limited: Business Overview, Financials & Competitive Analysis
Burning Rock Biotech Limited scores 6/10 on the AskCyborg Cyborg Score (Solid). Disciplined NGS oncology diagnostics player with dominant China position and early detection potential, but execution and revenue expansion require close monitoring. Burning Rock holds market leadership in China's NGS-based cancer testing market with strong regulatory recognition, including NMPA breakthrough designation for early cancer detection. However, revenue growth remains.
What is Burning Rock Biotech Limited's industry? Burning Rock Biotech Limited (brbiotech.com) operates in Biotechnology - Precision Oncology Diagnostics. AskCyborg classifies Burning Rock Biotech Limited under Biotechnology - Precision Oncology Diagnostics in its company registry.
Burning Rock Biotech is a precision oncology company focused on next-generation sequencing (NGS) technology applications for cancer diagnosis and treatment selection. Founded in 2014 and headquartered in Guangzhou, Ch...
Cyborg Score thesis
Disciplined NGS oncology diagnostics player with dominant China position and early detection potential, but execution and revenue...
Read the full analyst-debate transcript →Get the Latest Burning Rock Biotech Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBurning Rock Biotech Limited Overview
Pro stress-test →Burning Rock Biotech is a precision oncology company focused on next-generation sequencing (NGS) technology applications for cancer diagnosis and treatment selection. Founded in 2014 and headquartered in Guangzhou, China, the company is the market leader in NGS-based cancer therapy selection testing in China with three primary business segments: central laboratory testing, in-hospital diagnostic services, and pharmaceutical research services.
Strategic Profile
Pro stress-test →The company differentiates through proprietary NGS assays including OncoScreen, OncoCompass, and CanCatch platforms that enable both therapy selection and early cancer detection. Strategic partnerships with major pharmaceutical companies including AstraZeneca, Bayer, and Johnson & Johnson strengthen competitive positioning in companion diagnostics and clinical trial biomarker detection services.
Competitive Landscape
Pro stress-test →Burning Rock competes in the precision oncology diagnostics space against international players like Guardant Health and Myriad Genetics (with whom it has in-licensing agreements), as well as domestic Chinese competitors. Competitive advantages stem from dominant market share in China, established pharma relationships, regulatory approvals, and proprietary early detection technology platforms.
Industry Context
Burning Rock Biotech Limited operates in Biotechnology - Precision Oncology Diagnostics.
Key facts
Founded: 2014 · Headquarters: Guangzhou, China · Employees: 1001-5000 · Revenue: RMB128.6M (Q3 2024)